

## Image of the Month


**Type II Achalasia as the Initial Presentation of Systemic Sclerosis****Keywords:** Achalasia; Esophagus; Functional GI disease; Scleroderma**Type II Achalasia in a Patient with Scleroderma**

A 62-year-old female with a history of coronary artery disease and longstanding Raynaud's syndrome was referred to us for an assessment of noncardiac chest pain, dysphagia and nocturnal reflux. Esophagogastroduodenoscopy was unremarkable with no evidence of stricture or mass. High-resolution esophageal manometry showed Type II achalasia (Figure 1). Ambulatory 24-hour pH study showed no significant acid reflux. A year later, she presented with progression of Raynaud's. Physical examination demonstrated sclerodactyly, digital capillary dropout and chest wall telangiectasias. Bloodwork was significant for positive antinuclear antibody (1:80) and anticentromere antibody (1:320). She was subsequently diagnosed with

limited cutaneous systemic sclerosis. Follow-up manometry (3 years later) showed classic 'scleroderma esophagus' (Figure 2).

**Discussion**

Vasculopathy leading to smooth muscle atrophy and fibrotic replacement is thought to be responsible for the classic finding of 'scleroderma esophagus', characterized by hypotensive lower esophageal sphincter (LES) pressure and aperistalsis in the distal esophagus (1). However, an achalasia-like syndrome with incomplete LES relaxation has been reported in systemic sclerosis (SSc) patients. Park et al. first described aperistalsis and incomplete LES relaxation on conventional manometry in four of seven patients with known SSc (2). The finding of esophageal dilation and delayed esophageal




**Figure 1.** Clouse plot demonstrating Type II achalasia (integrated residual pressure = 19.2, normal < 15 mmHg; panesophageal pressurization with 70% of swallows).

Received: February 15, 2019; Accepted: June 17, 2019

© The Author(s) 2019. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)



**Figure 2.** Clouse plot demonstrating hypotensive lower esophageal sphincter, and absent peristalsis, consistent with 'scleroderma esophagus'.

emptying on barium study, associated with manometric evidence of aperistalsis with normal LES relaxation, was documented to precede autoantibody formation and skin changes in a patient who developed SSc; follow-up manometry demonstrated absent motor activity in the smooth muscle esophagus with absent LES tone (3). The pathophysiology of this finding is unclear but may relate to the presence of antimyenteric neuronal antibodies. Antimyenteric neuronal antibodies have been detected in the sera of SSc patients and correlate with the presence of Raynaud's phenomenon (4). Autoantibodies to the myenteric plexus have also been detected in achalasia patients, and may be implicated in the decreased interstitial cells of Cajal and nitric oxide synthase containing neurons seen on histopathologic examination (5). Our case is the first to document on high-resolution manometry the conversion of type II achalasia features to scleroderma esophagus findings. This may yield insight into the pathophysiology of esophageal disease in SSc, which remains poorly understood.

Grant support: none.

Disclosures: none.

Matthew Woo, MD<sup>o</sup>, Milli Gupta, MD

Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada

Correspondence: Matthew Woo, MD, FRCPC, Division of Gastroenterology, Department of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada, e-mail: [mwoo@qmed.ca](mailto:mwoo@qmed.ca)

## References

1. Savarino E, Furnari M, de Bortoli N, et al. Gastrointestinal involvement in systemic sclerosis. *Presse Med* 2014;43(10 Pt 2):e279–91.
2. Park RH, McKillop JH, Belch JJ, et al. Achalasia-like syndrome in systemic sclerosis. *Br J Surg* 1990;77(1):46–9.
3. Garrigues V, Ponce J, Gálvez C, et al. Achalasia-like syndrome as the first manifestation in a patient with CREST syndrome. *Eur J Gastroenterol Hepatol* 1996;8(3):289–91.
4. Howe S, Eaker EY, Sallustio JE, et al. Antimyenteric neuronal antibodies in scleroderma. *J Clin Invest* 1994;94(2):761–70.
5. Gockel I, Bohl JR, Eckardt VF, et al. Reduction of interstitial cells of Cajal (ICC) associated with neuronal nitric oxide synthase (n-NOS) in patients with achalasia. *Am J Gastroenterol* 2008;103(4):856–64.